Education
About Us
Working with TipRanks
Follow Us
CervoMed (CRVO)
NASDAQ:CRVO
CRVO Stock Chart & Stats
$4.53
-$0.11(-4.76%)
At close: 4:00 PM EST
$4.53
-$0.11(-4.76%)
Day’s Range― - ―
52-Week Range$1.92 - $16.94
Previous CloseN/A
Volume72.82K
Average Volume (3M)112.80K
Market Cap
$44.41M
Enterprise Value$34.24M
Total Cash (Recent Filing)$27.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding9,252,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue106.13
Enterprise Value/Gross Profit106.13
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$22.50Price Target Upside396.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-driven EnrollmentAnalyst highlights identification of a simple plasma biomarker and plans to enrich the pivotal trial with biomarker-selected patients, which should concentrate treatment on those most likely to benefit and improve chances of a positive outcome.
Clinical Efficacy SignalAnalyst cites Phase 2b results showing a meaningful cognitive benefit in a biomarker-defined subgroup and substantial slowing of disease progression, supporting the drug's potential efficacy in targeted DLB patients.
Regulatory AlignmentAnalyst notes FDA alignment to proceed directly to a randomized pivotal study with neflamapimod, providing a clearer regulatory pathway that supports advancement toward potential approval.
Bears Say
Assay ReliabilityPrevious conversion of assay data was not accurate, which impacted patient selection in earlier trials and raises concerns about biomarker reliability for future enrollment.
Development Timeline RiskAnalyst cautions that the substantial funding gap could delay trial initiation and enrollment, increasing uncertainty around the program's development timeline.
Financing RequirementAnalyst warns the company needs to raise roughly $70–90 million to complete the pivotal trial, creating a material financing risk for the development program.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $1.92 and its highest was $16.94 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $44.41M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is May 19, 2026 which is in 94 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Nov 10, 2025. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.657 by -$0.183.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CervoMed have?
CervoMed has 9,252,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.657. Following the earnings report the stock price went down -0.289%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (396.69% Upside)
$22.50 (396.69% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $630.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 12.8%
Last 30 Days ▼ 12.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
-71.42%
Trailing 12-Months
Asset Growth
-28.41%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CRVO Stock 12 Month Forecast
Average Price Target
$22.50
▲(396.69% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
44.10% Insiders
3.95% Mutual Funds
0.59% Other Institutional Investors
47.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---